ClinicalTrials.gg
Status unknownNCT00666354Updated Feb 10, 2009

Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis

A Phase 2 interventional study of Methotrexate and Methotrexate in Fingernail Psoriasis, sponsored by MediQuest Therapeutics. Status unknown at 7 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-02-10.

Sponsored by MediQuest Therapeutics · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2009), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing methotrexate in Psoriasis — 8 open to participants now, 8 under way, none of them phase 3. Methotrexate · Psoriasis.

Planned enrollment
12th of 31
83 · median 60
Started
2007
the only one that year
Phase 2
3 of 31
none open now
Registered
3rd of 31
by date

Among the 31 studies testing methotrexate in Psoriasis, this one is the 12th largest by planned enrollment, is the only one that started in 2007, is one of 3 in phase 2, and was the 3rd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 31 studies testing methotrexate in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing methotrexate in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.

Read the detailed description

The purpose of this clinical study is to compare, in a controlled fashion, the response to three concentrations of methotrexate in novel topical formulations in the treatment of subjects with psoriasis of the fingernails. Such a determination will be used as the basis for evidence of efficacy and safety of these formulations as a therapeutic treatment for fingernail psoriasis.

03

Conditions studied

  • Fingernail Psoriasis

Browse trials for

Keywords

  • Nail Psoriasis
  • Psoriasis
  • Fingernail Psoriasis
  • Methotrexate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed moderate fingernail psoriasis of at least two fingernails.
  • Stable and unchanged psoriasis therapies for 2 months and must not have received methotrexate for 3 months prior to screening.
  • Female patients who are not 5 years post menopausal or surgically sterile must use appropriate for specified time periods and have negative pregnancy tests.

Exclusion criteria

Exclusion Criteria:

  • Target or control fingernails that are thicker than 2mm, abnormal or infected (bacterial or fungal).
  • Patients with , , or neuropathies of the hand.
  • Use of any methotrexate preparation, any topical anti-psoriatic medications or ultraviolet treatment within 2 months of study visit 1.
  • Use of more that one 2-week course of oral therapy or one injection during 3 months prior to the screening visit.
  • Use of manicures or cosmetic nail products during and within 7 days of the start of treatment.
  • Use of any drug known to have potential for toxicity to a major organ during and within 90 days prior to the start of treatment.
  • Patients who are nursing, pregnant or plan to become pregnant or father a child within the study time frame including within three months of the last dose of study medication.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (estimated)

Study arms

  • Active comparator
    1

    Drug: Methotrexate

  • Active comparator
    2

    Drug: Methotrexate

  • Active comparator
    3

    Drug: Methotrexate

Interventions

  • 0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.

    Also known as: MQX-5906

  • 0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.

    Also known as: MQX-5902

  • 0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.

    Also known as: MQX-5904

06

What researchers measure

Primary outcomes

  1. Evaluate improvements in the appearance of the target fingernail, utilizing photography for imaging and independent photograph evaluators.

    Time frame: Monthly

Secondary outcomes

  1. Improvement in appearance of the control fingernail, improvement of the target fingernail using mNAPSI (a modification of the Nail Psoriasis Severity Index), and comparison of improvement of mNAPSI of the target and control fingernails.

    Time frame: Monthly

  2. Information on the relative changes in nail psoriasis severity of the other affected fingernails will be collected.

    Time frame: Monthly

  3. Comparison of nail growth of the target and control fingernails as determined from nail notch movement measured on nail photographs will be performed.

    Time frame: Monthly

  4. Assess safety, i.e., the frequency and severity of adverse events associated with MQX-5902, MQX-5904 and MQX-5906 in the treatment of patients with fingernail psoriasis.

    Time frame: Monthly

07

Study locations

7 sites
  • University of Manchester, The Dermatology Centre
    Salford, Manchester M6 8HD, United Kingdom
  • Great Western Hospital Rheumatology Department
    Swindon, Wiltshire SN3 6BB, United Kingdom
  • Aberdeen Royal Infirmary Dermatology Outpatients Clinic
    Aberdeen, AB25 2ZR, United Kingdom
  • Royal National Hospital for Rheumatic Diseases
    Bath, BA1 1RL, United Kingdom
  • University Hospital of Wales, Welsh Institute of Dermatology
    Cardiff, CF14 4XN, United Kingdom
  • Leeds General Infirmary Department of Dermatology
    Leeds, LS1 3EX, United Kingdom
  • George Eliot Hospital, Department of Dermatology
    Nuneaton, CV10 7DJ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Sep 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2008
First posted
Apr 24, 2008
Start
Oct 2007
Primary completionEst.
Sep 2008
CompletionEst.
Jan 2009
Last update
Feb 10, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00666354
Lead sponsor
MediQuest Therapeutics
First posted
Apr 24, 2008
Start date
Oct 2007
Primary completion
Sep 2008 (estimated)
Completion
Jan 2009 (estimated)
Last update
Feb 10, 2009

Study contacts

Prof. Neil McHugh
principal investigator · Royal National Hospital for Rheumatic Diseases

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion